Morris Named to Biote Board of Directors
8 November 2022 - - US-based personalized hormone therapy provider biote Corp. (NASDAQ: BTMD) has appointed Debby Morris to Biote's board of directors, the company said.

Morris brings more than three decades of experience in directing financial operations and strategy to support high-growth companies.

Morris served as the executive vice president and chief financial officer of Apria, Inc. from March 2013 through October 2022.

Prior to that, Morris served as chief financial officer-Americas for Sitel Worldwide Corp. from February 2010 to February 2013.

Prior to that she served as a partner of Tatum LLC from 2004 to 2010 and as a director from 2008 to 2010 and provided interim and permanent chief financial officer services for companies contracted with Tatum LLC including LifeMasters Supported SelfCare and RelaDyne.

Effective May 15, 2020, Morris serves as a director for Alternative Logistics Technologies, Holdco, LLC (a.k.a EverDriven) and serves as the chair of the audit committee.

Effective December 31, 2020, Morris serves as a director for Rexford Industrial and serves on the audit, compensation and nomination and governance committees.

Morris holds a B.S. in Business Administration from Colby Sawyer College in New London, New Hampshire.

Biote is addressing healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers.

Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved USD 7bn global market, providing affordable symptom relief for patients and driving clinic success for practitioners.